Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AAIC 2021

26–30 July 2021 | Denver, CO

AAIC 2021

26–30 July 2021 | Denver, CO
Changes in Rhes distribution associated with tau accumulation and neuronal vulnerability 4:13
Changes in Rhes distribution associated with tau accumulation and neuronal vulnerability
Lea Grinberg • 27 Aug 2021
Caspase-6-cleaved tau in Alzheimer’s disease 3:20
Caspase-6-cleaved tau in Alzheimer’s disease
Lea Grinberg • 27 Aug 2021
Investigating differences in selective neuronal vulnerability in typical and atypical AD 2:14
Investigating differences in selective neuronal vulnerability in typical and atypical AD
Lea Grinberg • 27 Aug 2021
Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease 4:36
Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease
Paul Edison • 29 Jul 2021
Mass spectrometry-based proteomics identifies progressive changes in tau PTMs over time 4:26
Mass spectrometry-based proteomics identifies progressive changes in tau PTMs over time
Judith Steen • 1 Sep 2021
Beyond amyloid & tau: neuroinflammation, rhes & proteomics 2:17
Beyond amyloid & tau: neuroinflammation, rhes & proteomics
Lea Grinberg • 27 Aug 2021
Advances in methodology for structural biology of neurodegeneration 1:38
Advances in methodology for structural biology of neurodegeneration
Judith Steen • 1 Sep 2021
Detecting microglial activation in Alzheimer’s disease 1:55
Detecting microglial activation in Alzheimer’s disease
Paul Edison • 27 Jul 2021
The impact of sex on Alzheimer’s disease presentation in adults with Down syndrome 3:33
The impact of sex on Alzheimer’s disease presentation in adults with Down syndrome
M. Florencia Iulita • 2 Aug 2021
Implementing the Humanitude care methodology in Japan 8:24
Implementing the Humanitude care methodology in Japan
Miwako Honda • 10 Aug 2021
The potential of lecanemab for the treatment of early Alzheimer’s disease 1:38
The potential of lecanemab for the treatment of early Alzheimer’s disease
Chad Swanson • 13 Aug 2021
Age at onset of Alzheimer’s disease is consistent in adults with Down syndrome 3:04
Age at onset of Alzheimer’s disease is consistent in adults with Down syndrome
M. Florencia Iulita • 2 Aug 2021
AD pathology isn’t always associated with memory loss 1:58
AD pathology isn’t always associated with memory loss
Lea Grinberg • 27 Aug 2021
Using AI to analyze the effectiveness of Humanitude training for paramedics in Japan 7:30
Using AI to analyze the effectiveness of Humanitude training for paramedics in Japan
Miwako Honda • 10 Aug 2021
The potential of plasma biomarkers in dementia 2:57
The potential of plasma biomarkers in dementia
Stephen Salloway • 13 Aug 2021
Donanemab: breakthrough therapy designation based on TRAILBLAZER data 3:10
Donanemab: breakthrough therapy designation based on TRAILBLAZER data
Stephen Salloway • 13 Aug 2021
The content of VJDementia is intended for healthcare professionals